Agoracom: Small Cap Investment - Zenith Epigenetics

No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Re: Great Presetation today

BearDownAZ

Oct 17, 2017 03:14PM

Re: Great Presetation today

bfw

Oct 17, 2017 07:16PM

Re: Great Presetation today

BearDownAZ

Oct 18, 2017 06:20AM

Re: Great Presetation today

fouremm

Oct 18, 2017 02:17PM

Re: Great Presetation today

BearDownAZ

Oct 18, 2017 04:27PM

Re: Great Presetation today

tada

Oct 18, 2017 06:11PM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Great Presetation today

in response to

Re: Great Presetation today

tada

posted on Oct 19, 2017 09:40AM

I think we are saying the same thing.

If the funds raised are through Zenith Capital Corp then this would be dilutive to the royalty preferred shares. If the funds are raised through Zenith Epigenetics Ltd, then it should not be dilutive to the royalty preferred shares. Is it possible to just raise funds through Zenith Epigenetics Ltd, since it is a subsidiary company 100% owned by Zenith Capital Corp?

BearDownAZ

3 Recommendations

Re: Great Presetation today

fouremm

Oct 19, 2017 10:45AM

Re: Great Presetation today

KayakerBC

Oct 19, 2017 02:51PM

Re: Great Presetation today

fouremm

Oct 19, 2017 07:22PM

Re: Great Presetation today